HippoFi (OTC: ORHB), formerly ORHub Inc., and its wholly owned subsidiary, PUR Biologics, has received a new patent; according to the announcement, the patent covers advanced cartilage regeneration and arthritis solutions that mark a significant advancement in treating the destructive effects of osteoarthritis and cartilage degeneration. The company stated that this addition to its intellectual property portfolio gives PUR Biologics “exclusive rights to innovative methods and compositions that utilize induced Pluripotent Stem Cells (‘iPSCs’) to produce an advanced extracellular matrix (‘ECM’). . .[heralding] a transformative phase in spine and orthopedic treatments.” The announcement noted that the need for effective cartilage regeneration solutions is increasing. The global cartilage repair market is forecast to reach $3.5 billion by 2028, and PUR Biologics has strengthened its position in the market with this new patent. “This patent reflects our ambition in the biotech market, which was estimated at $1.37 trillion in 2022 and is expected to grow at a compound annual growth rate (‘CAGR’) of 13.96% from 2023 to 2030,” said HippoFi CEO and executive chair CJ Wiggins in the press release. “We’re excited about the advancement of iPSC-ECM and the promising future to regenerate cartilage, along with our broader vision to remain at the forefront of biotechnological innovations, driving unparalleled value to our investors.”
To view the full press release, visit https://ibn.fm/RxzJY
About HippoFi Inc.
HippoFi, formerly ORHub Inc., delivers its cutting-edge healthcare innovations and propriety technologies through an extensive sales channel network, while implementing first-to-market solutions in the multibillion-dollar biotech, fintech and artificial intelligence (“AI”) markets. HippoFi comprises three segments — regenerative therapeutics, digital payments and AI — and utilizes the same customer channels to commercialize solutions, drive revenue and improve patient outcomes. For more information, visit the company’s website at www.HippoFi.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
